Literature DB >> 22180144

Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred.

Carol A Durno1, Melyssa Aronson, Uri Tabori, David Malkin, Steven Gallinger, Helen S L Chan.   

Abstract

BACKGROUND: Heterozygous germline mutations in DNA mismatch repair (MMR) genes cause Lynch syndrome. Biallelic MMR mutations cause a distinct syndrome characterized by brain tumors, lymphoid malignancies, and gastrointestinal cancers during childhood. These children usually succumb to multiple cancers before adulthood. We developed a surveillance protocol aiming at early detection for these individuals and report the 10-year experience with a kindred.
METHODS: On the basis of genetic testing and early age tumors, the kindred started a cancer surveillance protocol based on the crude estimates of cancer risks and available cancer screening: imaging, endoscopy, and hematologic tests.
RESULTS: Over the 10-year follow-up period, the screening protocol detected 15 tumors. These included three high-grade adenomatous colonic polyps and two colon cancers. In one child, MRI revealed an asymptomatic anaplastic astrocytoma which was treated by complete resection and radiation. All three cancers identified during surveillance were small and asymptomatic at diagnosis. The two sisters are currently 16 and 18 years of age with no evidence of malignant disease. Both parents have annual colonoscopies and the father at 43 years had two colonic adenomatous polyps.
CONCLUSIONS: We report on the long-term outcome in patients with biallelic MMR mutations who benefited from prophylactic cancer surveillance. Genetic screening and subsequent surveillance led to earlier recognition of asymptomatic tumors at stages more amenable to resection and probable cure. Multicenter collaboration and implementation of surveillance guidelines is necessary to further determine genotype-phenotype correlations.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22180144     DOI: 10.1002/pbc.24019

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  18 in total

1.  Predictive genetic testing in children: constitutional mismatch repair deficiency cancer predisposing syndrome.

Authors:  Zandrè Bruwer; Ursula Algar; Alvera Vorster; Karen Fieggen; Alan Davidson; Paul Goldberg; Helen Wainwright; Rajkumar Ramesar
Journal:  J Genet Couns       Date:  2013-10-15       Impact factor: 2.537

2.  Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation.

Authors:  Nisreen Amayiri; Maysa Al-Hussaini; Maisa Swaidan; Imad Jaradat; Monther Qandeel; Uri Tabori; Cynthia Hawkins; Awni Musharbash; Khulood Alsaad; Eric Bouffet
Journal:  Childs Nerv Syst       Date:  2015-08-21       Impact factor: 1.475

3.  Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.

Authors:  Chen Yang; Frances Austin; Hope Richard; Michael Idowu; Vernell Williamson; Fernanda Sabato; Andrea Ferreira-Gonzalez; Scott A Turner
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-10-23

4.  Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium.

Authors:  Melyssa Aronson; Steven Gallinger; Zane Cohen; Shlomi Cohen; Rina Dvir; Ronit Elhasid; Hagit N Baris; Revital Kariv; Harriet Druker; Helen Chan; Simon C Ling; Paul Kortan; Spring Holter; Kara Semotiuk; David Malkin; Roula Farah; Alain Sayad; Brandie Heald; Matthew F Kalady; Lynette S Penney; Andrea L Rideout; Mohsin Rashid; Linda Hasadsri; Pavel Pichurin; Douglas Riegert-Johnson; Brittany Campbell; Doua Bakry; Hala Al-Rimawi; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Uri Tabori; Carol Durno
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

Review 5.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

6.  Pitfalls in the diagnosis of biallelic PMS2 mutations.

Authors:  Marina Antelo; Daniela Milito; Jennifer Rhees; Enrique Roca; Miguel Barugel; Miriam Cuatrecasas; Leticia Moreira; Maria Liz Leoz; Sabela Carballal; Teresa Ocaña; Maria Pellisé; Antoni Castells; C Richard Boland; Ajay Goel; Francesc Balaguer
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

7.  Agenesis of the corpus callosum and gray matter heterotopia in three patients with constitutional mismatch repair deficiency syndrome.

Authors:  Annette F Baas; Michael Gabbett; Milan Rimac; Minttu Kansikas; Martine Raphael; Rutger Aj Nievelstein; Wayne Nicholls; Johan Offerhaus; Danielle Bodmer; Annekatrin Wernstedt; Birgit Krabichler; Ulrich Strasser; Minna Nyström; Johannes Zschocke; Stephen P Robertson; Mieke M van Haelst; Katharina Wimmer
Journal:  Eur J Hum Genet       Date:  2012-06-13       Impact factor: 4.246

Review 8.  Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).

Authors:  Erika K S M Leenders; Harm Westdorp; Roger J Brüggemann; Jan Loeffen; Christian Kratz; John Burn; Nicoline Hoogerbrugge; Marjolijn C J Jongmans
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

9.  Metachronous T-Lymphoblastic Lymphoma and Burkitt Lymphoma in a Child With Constitutional Mismatch Repair Deficiency Syndrome.

Authors:  Thomas B Alexander; Rose B McGee; Erica C Kaye; Mary Beth McCarville; John K Choi; Cary P Cavender; Kim E Nichols; John T Sandlund
Journal:  Pediatr Blood Cancer       Date:  2016-04-01       Impact factor: 3.167

Review 10.  Imaging surveillance for children with predisposition to renal tumors.

Authors:  Abhay S Srinivasan; Sandra Saade-Lemus; Sabah E Servaes; Michael R Acord; Janet R Reid; Sudha A Anupindi; Lisa J States
Journal:  Pediatr Radiol       Date:  2019-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.